Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

January 2023

Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

 Jan 19, 2023, 07:30 ET  –  BREAKOUT Study is Palatin’s third clinical program for the potential treatment of inflammatory diseases with melanocortin agonists –  Primary endpoint of the BREAKOUT Study is a 50% reduction in urine protein/creatinine (UP/Cr) ratio after six months of combined therapy (RAAS inhibition therapy plus bremelanotide) CRANBURY, N.J., Jan. 19, 2023 …

Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease Read More »

Palatin Receives $4.7 Million of Non-Dilutive Funding

 Jan 18, 2023, 07:30 ET  Sells Net Operating Loss Tax Benefits Through New Jersey Economic Development Program CRANBURY, N.J., Jan. 18, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it has received approximately $4.7 …

Palatin Receives $4.7 Million of Non-Dilutive Funding Read More »

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions

 Jan 10, 2023, 07:30 ET  –  Collaboration with The William Harvey Research Institute and Queen Mary University of London –  PL-8177 displayed pro-resolving and anti-arthritic effects in rodents CRANBURY, N.J., Jan. 10, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced Frontiers …

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions Read More »

Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results

 Jan 05, 2023, 07:30 ET  15.4% increase in net product revenue over the prior quarter 1,290% increase over the comparable quarter in 2021 11.5% increase in prescriptions dispensed over the prior quarter Increased 134% over the comparable quarter in 2021 CRANBURY, N.J., January 5, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical …

Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results Read More »

Scroll to Top